Which has higher valuation & earnings, SION or CTOR?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is SION or CTOR more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Citius Oncology N/A -99.47% -42.16%

Does the media favor SION or CTOR?

In the previous week, Sionna Therapeutics had 42 more articles in the media than Citius Oncology. MarketBeat recorded 49 mentions for Sionna Therapeutics and 7 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat Sionna Therapeutics' score of -0.30 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 11 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTOR or RNAC?

In the previous week, Cartesian Therapeutics had 8 more articles in the media than Citius Oncology. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 7 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat Cartesian Therapeutics' score of 0.58 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is ACIU or CTOR more profitable?

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Citius Oncology's return on equity of -99.47% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Citius Oncology N/A -99.47% -42.16%

Does the media favor ACIU or CTOR?

In the previous week, AC Immune had 2 more articles in the media than Citius Oncology. MarketBeat recorded 9 mentions for AC Immune and 7 mentions for Citius Oncology. AC Immune's average media sentiment score of 1.33 beat Citius Oncology's score of 0.63 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTOR or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Q32 Bio N/A 50.17% 29.49%

Does the media prefer CTOR or QTTB?

In the previous week, Citius Oncology had 3 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Citius Oncology and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.17 beat Citius Oncology's score of 0.63 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or CTOR more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -53.89% -49.97% Citius Oncology N/A -99.47% -42.16%

Does the media favor WHWK or CTOR?

In the previous week, Citius Oncology had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 7 mentions for Citius Oncology and 5 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Citius Oncology's score of 0.63 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Citius Oncology (CTOR) Competitors

$0.91 +0.08 (+10.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 -0.16 (-18.00%)

As of 07:59 PM Eastern

Compare

CTOR vs. SION, RNAC, ACIU, QTTB, and WHWK

Should you buy Citius Oncology stock or one of its competitors? Citius Oncology's main competitors and comparable companies include Sionna Therapeutics (SION), Cartesian Therapeutics (RNAC), AC Immune (ACIU), Q32 Bio (QTTB), and Whitehawk Therapeutics (WHWK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Citius Oncology compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Citius Oncology	N/A	-99.47%	-42.16%

70.5% of Citius Oncology shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by insiders. Comparatively, 9.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sionna Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market.

In the previous week, Sionna Therapeutics had 42 more articles in the media than Citius Oncology. MarketBeat recorded 49 mentions for Sionna Therapeutics and 7 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat Sionna Therapeutics' score of -0.30 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	11 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics currently has a consensus price target of $42.22, suggesting a potential upside of 553.59%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 559.49%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Citius Oncology beats Sionna Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Citius Oncology compare to Cartesian Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Citius Oncology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 559.49%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 268.78%. Given Citius Oncology's higher possible upside, analysts plainly believe Citius Oncology is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Citius Oncology has a beta of 3.48, meaning that its stock price is 248% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, Cartesian Therapeutics had 8 more articles in the media than Citius Oncology. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 7 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.63 beat Cartesian Therapeutics' score of 0.58 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Citius Oncology has higher earnings, but lower revenue than Cartesian Therapeutics. Citius Oncology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Cartesian Therapeutics	$1.48M	181.08	-$130.30M	-$5.94	N/A

Summary

Cartesian Therapeutics beats Citius Oncology on 9 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Citius Oncology's return on equity of -99.47% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Citius Oncology	N/A	-99.47%	-42.16%

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 201.20%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 559.49%. Given Citius Oncology's higher probable upside, analysts plainly believe Citius Oncology is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, suggesting that its stock price is 248% more volatile than the broader market.

In the previous week, AC Immune had 2 more articles in the media than Citius Oncology. MarketBeat recorded 9 mentions for AC Immune and 7 mentions for Citius Oncology. AC Immune's average media sentiment score of 1.33 beat Citius Oncology's score of 0.63 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Oncology has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	58.80	-$85.03M	-$0.54	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Citius Oncology beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Q32 Bio?

Citius Oncology (NASDAQ:CTOR) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Q32 Bio has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Q32 Bio	$53.74M	8.39	$29.82M	$3.00	5.05

Citius Oncology has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Q32 Bio's return on equity of 50.17% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Q32 Bio	N/A	50.17%	29.49%

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 559.49%. Q32 Bio has a consensus target price of $30.00, indicating a potential upside of 98.02%. Given Citius Oncology's higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Citius Oncology had 3 more articles in the media than Q32 Bio. MarketBeat recorded 7 mentions for Citius Oncology and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.17 beat Citius Oncology's score of 0.63 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Q32 Bio beats Citius Oncology on 10 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Whitehawk Therapeutics' return on equity of -53.89% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Citius Oncology	N/A	-99.47%	-42.16%

In the previous week, Citius Oncology had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 7 mentions for Citius Oncology and 5 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Citius Oncology's score of 0.63 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 83.86%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 559.49%. Given Citius Oncology's higher probable upside, analysts clearly believe Citius Oncology is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Whitehawk Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Citius Oncology. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Whitehawk Therapeutics and Citius Oncology tied by winning 7 of the 14 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$76.88M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.94	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.68	16.78	12.91	6.24
Net Income	-$24.76M	-$13.32M	$3.45B	$347.60M
7 Day Performance	20.82%	1.74%	1.12%	1.07%
1 Month Performance	39.97%	1.60%	1.79%	1.03%
1 Year Performance	-47.10%	56.43%	67.69%	20.77%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	2.0021 of 5 stars	$0.91 +10.0%	$6.00 +559.5%	-53.8%	$76.88M	N/A	N/A	N/A	News Coverage Earnings Report High Trading Volume
SION Sionna Therapeutics	3.01 of 5 stars	$5.98 +17.2%	$42.22 +606.6%	-68.7%	$268.83M	N/A	N/A	35	Gap Down High Trading Volume
RNAC Cartesian Therapeutics	2.4076 of 5 stars	$8.70 +1.2%	$32.60 +274.9%	-25.5%	$263.34M	$1.48M	N/A	64	Analyst Revision
ACIU AC Immune	2.7084 of 5 stars	$2.57 +1.0%	$7.50 +192.4%	+16.8%	$261.04M	$4.31M	N/A	140	Positive News Analyst Revision Gap Up
QTTB Q32 Bio	4.5767 of 5 stars	$15.38 -0.2%	$30.00 +95.1%	+749.2%	$260.72M	$53.74M	5.13	39	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. SION, RNAC, ACIU, QTTB, and WHWK

How does Citius Oncology compare to Sionna Therapeutics?

Summary

How does Citius Oncology compare to Cartesian Therapeutics?

Summary

How does Citius Oncology compare to AC Immune?

Summary

How does Citius Oncology compare to Q32 Bio?

Summary

How does Citius Oncology compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. SION, RNAC, ACIU, QTTB, and WHWK

How does Citius Oncology compare to Sionna Therapeutics?

Is SION or CTOR more profitable?

Do insiders and institutionals hold more shares of SION or CTOR?

Which has more risk & volatility, SION or CTOR?

Does the media favor SION or CTOR?

Do analysts rate SION or CTOR?

Which has higher valuation & earnings, SION or CTOR?

Summary

How does Citius Oncology compare to Cartesian Therapeutics?

Is CTOR or RNAC more profitable?

Do analysts rate CTOR or RNAC?

Do institutionals & insiders believe in CTOR or RNAC?

Which has more volatility & risk, CTOR or RNAC?

Does the media prefer CTOR or RNAC?

Which has stronger valuation and earnings, CTOR or RNAC?

Summary

How does Citius Oncology compare to AC Immune?

Is ACIU or CTOR more profitable?

Do analysts prefer ACIU or CTOR?

Do insiders & institutionals believe in ACIU or CTOR?

Which has more risk & volatility, ACIU or CTOR?

Does the media favor ACIU or CTOR?

Which has higher earnings and valuation, ACIU or CTOR?

Summary

How does Citius Oncology compare to Q32 Bio?

Which has preferable earnings & valuation, CTOR or QTTB?

Which has more risk & volatility, CTOR or QTTB?

Is CTOR or QTTB more profitable?

Do analysts recommend CTOR or QTTB?

Does the media prefer CTOR or QTTB?

Do institutionals & insiders have more ownership in CTOR or QTTB?

Summary

How does Citius Oncology compare to Whitehawk Therapeutics?

Is WHWK or CTOR more profitable?

Does the media favor WHWK or CTOR?

Do insiders & institutionals hold more shares of WHWK or CTOR?

Do analysts rate WHWK or CTOR?

Which has more volatility and risk, WHWK or CTOR?

Which has better valuation and earnings, WHWK or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools